| Reference |
|---|
Anthi A, Kolderup A, Vaage E, Bern M, Benjakul S, Tj xe4 rnhage E, et al. An intranasal subunit vaccine induces protective systemic and mucosal antibody immunity against respiratory viruses in mouse models. Nat Commun. 2025;16:3999 pubmed publisher |
Wang J, Zhou Q, Lowry K, Howard C, Trau M. Development and application of multivalent nanobody-functionalized plasmonic probes in SERS sensing platforms. Biosens Bioelectron. 2025;278:117292 pubmed publisher |
Bui D, Kitova E, Kitov P, Han L, Mahal L, Klassen J. Deciphering Pathways and Thermodynamics of Protein Assembly Using Native Mass Spectrometry. J Am Chem Soc. 2024;146:28809-28821 pubmed publisher |
Parkinson J, Hard R, Ko Y, Wang W. RESP2: An uncertainty aware multi-target multi-property optimization AI pipeline for antibody discovery. bioRxiv. 2024;: pubmed publisher |
Yu W, Yi S, Jiang C, Guan J, Xue R, Zhang X, et al. Biosensor-based active ingredient recognition system for screening potential small molecular Severe acute respiratory syndrome coronavirus 2 entry blockers targeting the spike protein from Rugosa rose. Biomed Chromatogr. 2024;38:e5987 pubmed publisher |
Shang J, Li H, Liu X, Sun S, Huan S, Xiong B. Single-particle rotational sensing for analyzing the neutralization activity of antiviral antibodies. Talanta. 2024;279:126606 pubmed publisher |
Baldelli A, Jerry Wong C, Oguzlu H, Gholizadeh H, Guo Y, Ong H, et al. Nasal delivery of encapsulated recombinant ACE2 as a prophylactic drug for SARS-CoV-2. Int J Pharm. 2024;655:124009 pubmed publisher |
Mahalingam G, Arjunan P, Periyasami Y, Dhyani A, Devaraju N, Rajendiran V, et al. Correlating the differences in the receptor binding domain of SARS-CoV-2 spike variants on their interactions with human ACE2 receptor. Sci Rep. 2023;13:8743 pubmed publisher |
Kaku C, Starr T, Zhou P, Dugan H, Khalif xe9 P, Song G, et al. Evolution of antibody immunity following Omicron BA.1 breakthrough infection. Nat Commun. 2023;14:2751 pubmed publisher |
Ouyang Y, Chen Y, Shang J, Sun S, Wang X, Huan S, et al. Virus-like Plasmonic Nanoprobes for Quick Analysis of Antiviral Efficacy and Mutation-Induced Drug Resistance. Anal Chem. 2023;95:5009-5017 pubmed publisher |
He S, Wang J, Chen H, Qian Z, Hu K, Shi B, et al. A Competitive Panning Method Reveals an Anti-SARS-CoV-2 Nanobody Specific for an RBD-ACE2 Binding Site. Vaccines (Basel). 2023;11: pubmed publisher |
Li M, Zhang Y, Zeb A, Wu Y, Cheng L. Bergamottin and PAP-1 Induced ACE2 Degradation to Alleviate Infection of SARS-CoV-2. Int J Mol Sci. 2022;23: pubmed publisher |
Song J, Chow R, Pe xf1 a Hern xe1 ndez M, Zhang L, Loeb S, So E, et al. LRRC15 inhibits SARS-CoV-2 cellular entry in trans. PLoS Biol. 2022;20:e3001805 pubmed publisher |
Ren P, Hu Y, Peng L, Yang L, Suzuki K, Fang Z, et al. Function and Cryo-EM structures of broadly potent bispecific antibodies against multiple SARS-CoV-2 Omicron sublineages. bioRxiv. 2022;: pubmed publisher |
Liu Y, Liu J, Johnson B, Xia H, Ku Z, Schindewolf C, et al. Delta spike P681R mutation enhances SARS-CoV-2 fitness over Alpha variant. Cell Rep. 2022;39:110829 pubmed publisher |
Petrenko V, Gillespie J, De Plano L, Shokhen M. Phage-Displayed Mimotopes of SARS-CoV-2 Spike Protein Targeted to Authentic and Alternative Cellular Receptors. Viruses. 2022;14: pubmed publisher |
Liang Y, Zhang J, Yuan R, Wang M, He P, Su J, et al. Design of a mutation-integrated trimeric RBD with broad protection against SARS-CoV-2. Cell Discov. 2022;8:17 pubmed publisher |
Ho T, Du P, Su W, Santos H, Lin Y, Chou Y, et al. Development of SARS-CoV-2 variant protein microarray for profiling humoral immunity in vaccinated subjects. Biosens Bioelectron. 2022;204:114067 pubmed publisher |
Ehling R, Weber C, Mason D, Friedensohn S, Wagner B, Bieberich F, et al. SARS-CoV-2 reactive and neutralizing antibodies discovered by single-cell sequencing of plasma cells and mammalian display. Cell Rep. 2022;38:110242 pubmed publisher |
Duan X, Shi Y, Zhang X, Ge X, Fan R, Guo J, et al. Dual-detection fluorescent immunochromatographic assay for quantitative detection of SARS-CoV-2 spike RBD-ACE2 blocking neutralizing antibody. Biosens Bioelectron. 2022;199:113883 pubmed publisher |
Liu Y, Liu J, Plante K, Plante J, Xie X, Zhang X, et al. The N501Y spike substitution enhances SARS-CoV-2 infection and transmission. Nature. 2022;602:294-299 pubmed publisher |
Asandei A, Mereuta L, Schiopu I, Park Y, Luchian T. Teaching an old dog new tricks: A lipid membrane-based electric immunosensor for real-time probing of the spike S1 protein subunit from SARS-CoV-2. Proteomics. 2022;22:e2100047 pubmed publisher |
Gunnels T, Stranford D, Mitrut R, Kamat N, Leonard J. Elucidating design principles for engineering cell-derived vesicles to inhibit SARS-CoV-2 infection. bioRxiv. 2021;: pubmed publisher |
Kim S, Liu Y, Lei Z, Dicker J, Cao Y, Zhang X, et al. Differential Interactions between Human ACE2 and Spike RBD of SARS-CoV-2 Variants of Concern. J Chem Theory Comput. 2021;17:7972-7979 pubmed publisher |
Song J, Chow R, Pena Hernandez M, Zhang L, Loeb S, So E, et al. LRRC15 is an inhibitory receptor blocking SARS-CoV-2 spike-mediated entry in trans. bioRxiv. 2021;: pubmed publisher |
Chang X, Zeltins A, Mohsen M, Gharailoo Z, Zha L, Liu X, et al. A Novel Double Mosaic Virus-like Particle-Based Vaccine against SARS-CoV-2 Incorporates Both Receptor Binding Motif (RBM) and Fusion Domain. Vaccines (Basel). 2021;9: pubmed publisher |
Wholey W, Yoda S, Cheng W. Site-Specific and Stable Conjugation of the SARS-CoV-2 Receptor-Binding Domain to Liposomes in the Absence of Any Other Adjuvants Elicits Potent Neutralizing Antibodies in BALB/c Mice. Bioconjug Chem. 2021;32:2497-2506 pubmed publisher |
Hojjat Jodaylami M, Djaïleb A, Ricard P, Lavallée É, Cellier Goetghebeur S, Parker M, et al. Cross-reactivity of antibodies from non-hospitalized COVID-19 positive individuals against the native, B.1.351, B.1.617.2, and P.1 SARS-CoV-2 spike proteins. Sci Rep. 2021;11:21601 pubmed publisher |
Pan X, Shi J, Hu X, Wu Y, Zeng L, Yao Y, et al. RBD-homodimer, a COVID-19 subunit vaccine candidate, elicits immunogenicity and protection in rodents and nonhuman primates. Cell Discov. 2021;7:82 pubmed publisher |
Liu Y, Liu J, Johnson B, Xia H, Ku Z, Schindewolf C, et al. Delta spike P681R mutation enhances SARS-CoV-2 fitness over Alpha variant. bioRxiv. 2021;: pubmed publisher |
Passariello M, Vetrei C, Amato F, De Lorenzo C. Interactions of Spike-RBD of SARS-CoV-2 and Platelet Factor 4: New Insights in the Etiopathogenesis of Thrombosis. Int J Mol Sci. 2021;22: pubmed publisher |
Ouyang W, Xie T, Fang H, Gao C, Stantchev T, Clouse K, et al. Variable Induction of Pro-Inflammatory Cytokines by Commercial SARS CoV-2 Spike Protein Reagents: Potential Impacts of LPS on In Vitro Modeling and Pathogenic Mechanisms In Vivo. Int J Mol Sci. 2021;22: pubmed publisher |
Ku Z, Xie X, Hinton P, Liu X, Ye X, Muruato A, et al. Nasal delivery of an IgM offers broad protection from SARS-CoV-2 variants. Nature. 2021;595:718-723 pubmed publisher |
Passariello M, Gentile C, Ferrucci V, Sasso E, Vetrei C, Fusco G, et al. Novel human neutralizing mAbs specific for Spike-RBD of SARS-CoV-2. Sci Rep. 2021;11:11046 pubmed publisher |
Guo Y, Huang L, Zhang G, Yao Y, Zhou H, Shen S, et al. A SARS-CoV-2 neutralizing antibody with extensive Spike binding coverage and modified for optimal therapeutic outcomes. Nat Commun. 2021;12:2623 pubmed publisher |
Liu Y, Liu J, Plante K, Plante J, Xie X, Zhang X, et al. The N501Y spike substitution enhances SARS-CoV-2 transmission. bioRxiv. 2021;: pubmed publisher |
Zhu Z, Qiu X, Wu S, Liu Y, Zhao T, Sun Z, et al. Blocking Effect of Demethylzeylasteral on the Interaction between Human ACE2 Protein and SARS-CoV-2 RBD Protein Discovered Using SPR Technology. Molecules. 2020;26: pubmed publisher |
Hanson Q, Wilson K, Shen M, Itkin Z, Eastman R, Shinn P, et al. Targeting ACE2-RBD Interaction as a Platform for COVID-19 Therapeutics: Development and Drug-Repurposing Screen of an AlphaLISA Proximity Assay. ACS Pharmacol Transl Sci. 2020;3:1352-1360 pubmed publisher |
Daly J, Simonetti B, Klein K, Chen K, Williamson M, Antón Plágaro C, et al. Neuropilin-1 is a host factor for SARS-CoV-2 infection. Science. 2020;370:861-865 pubmed publisher |
Piccoli L, Park Y, Tortorici M, Czudnochowski N, Walls A, Beltramello M, et al. Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology. Cell. 2020;183:1024-1042.e21 pubmed publisher |
Chi X, Liu X, Wang C, Zhang X, Li X, Hou J, et al. Humanized single domain antibodies neutralize SARS-CoV-2 by targeting the spike receptor binding domain. Nat Commun. 2020;11:4528 pubmed publisher |
Lv Z, Deng Y, Ye Q, Cao L, Sun C, Fan C, et al. Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody. Science. 2020;369:1505-1509 pubmed publisher |
Hanson Q, Wilson K, Shen M, Itkin Z, Eastman R, Shinn P, et al. Targeting ACE2-RBD interaction as a platform for COVID19 therapeutics: Development and drug repurposing screen of an AlphaLISA proximity assay. bioRxiv. 2020;: pubmed publisher |
Tennenbaum J. Immunologic deficiency states. A review. Ohio State Med J. 1966;62:1157-61 pubmed |
